News & Announcements

How do you turn an interesting antibody response into an assay that works beyond the discovery platform? Two Biotome webinars, hosted by our long-standing partner PEPperPRINT and now available on YouTube, explore that journey from different starting points. CEO Dr Samuel Lundin shares the development of Helitope, our peptide-based anti-CagA IgG ELISA. CTO Luke Marshall takes a step further back, showing how our team approaches biomarker discovery when the target antigen is no

Biotome has launched its first commercial product, the Helitope® RUO Rapid Human anti-CagA Epitope IgG ELISA Kit.

Biotome is pleased to announce the arrival of our first prototype diagnostic test kits from manufacturing partner Biosensis Pty Ltd. These kits represent the culmination of years of research into precision detection of high-virulence Helicobacter pylori strains that significantly elevate gastric cancer risk.

Tuesday, July 5th, 2022 - Perth, Australia: Biotome has been awarded $497,000 in funding from the Western Australian Future Health Research & Innovation Fund , to develop their precision diagnostic for stomach cancer risk. This test will be the world’s first diagnostic for stomach cancer risk with high enough accuracy and a low enough cost to be used for public health screening. It has the potential to save thousands of lives in Australia, and millions around the world. Biot